[ad_1]
In the news reported in the US media, it was noted that the US Food and Drug Administration (FDA) gave the green light to both companies to continue their vaccine trials.
It was stated that the illnesses that occurred in the subjects that caused the discontinuation of the studies were reviewed by the FDA’s independent investigative committee and decided not to be caused by the Kovid-19 vaccine.
AstraZeneca CEO Pascal Soriot said, “The relaunch of clinical trials around the world is great news because we must continue our efforts to develop this vaccine to help conquer this terrible pandemic.” shared his statements.
Second-phase vaccine trials conducted by the company AstraZeneca with the University of Oxford against the Kovid-19 virus were suspended in the US due to a neurological problem in one of the subjects on September 6.
In addition to cosmetic and hygienic products, drug and medical equipment maker Johnson and Johnson announced on October 12 that a participant in the trials of the Kovid-19 vaccine became ill.
Johnson and Johnson signed a $ 1 billion agreement with the United States government for the production and delivery of 100 million doses of the Kovid-19 vaccine on August 5.
